Floatz logo

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301)

Pancreatic Cancer

Washington University School of Medicineprotein_peptidePhase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

381 Active assets in the Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Irinotecan
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301) is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
ductal breast carcinoma in situDormant
CCC
Indicative ·
51 / 100
View asset →
invasive ductal breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →